Tilray | TRLY - Operating Profit


Tilray reported $-20.01M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acasti Pharma USD -2.53M 560K Sep/2025
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alaunos Therapeutics USD -952K 60K Jun/2026
Aurora Cannabis CAD -8.73M 1.3M Jun/2026
Avita Medical AUD -6.86M 3.55M Jun/2026
Canopy Growth CAD -17.58M 9.9M Jun/2026
Cronos Group USD 96.96M 89.36M Sep/2026
Dianthus Therapeutics USD -61.48M 14.95M Jun/2026
Divis Laboratories Ltd INR 14.24B 2.95B Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
IQVIA Holdings USD 608M 1.99B Sep/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Moderna USD 130M 945M Sep/2026
Organigram Holdings CAD 5.33M 15.12M Jun/2026
Organon & Co USD 377M 54M Sep/2026
Revvity USD 124.63M 1.51M Sep/2026
Tectonic Therapeutic USD -24.22M 3.08M Jun/2026
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD 255.5M 181.8M Sep/2026
Xeris Pharmaceuticals USD 5.17M 2.74M Jun/2026
Zealand Pharma A/S -539M 168.05M Mar/2026